Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Pembrolizumab in HRD+ Advanced Pancreatic Cancer
NCT03432676Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of epacadostat in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Best Objective Response Rate up to 2 years. Planned start Jul 2019; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03432676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432676.